Friday, October 16, 2026
Close-up of a pharmaceutical manufacturing m
UIP fill line in the UI College of Pharmacy building.

For Bill Vincent, the new executive director of University of Iowa Pharmaceuticals (UIP), the path is straightforward: build on the organization’s longstanding expertise, strengthen its connections across the pharmaceutical and biotechnology industries, and bring its capabilities to a wider audience.

Vincent brings extensive leadership experience in the pharmaceutical and biotechnology industries, including a track record of expanding organizations, developing strategic partnerships, advancing business development, and building high-performing teams.

“Bill has demonstrated a clear vision for the future of UI Pharmaceuticals, a deep understanding of the evolving pharmaceutical landscape, and a commitment to a people-first culture,” said Jill Kolesar, UI College of Pharmacy dean, Jean M. Schmidt chair, and professor. “I am confident his experience and leadership will help strengthen UI Pharmaceuticals’ impact 
while positioning the organization for future growth and new opportunities.”

Experience Alignment

Vincent was drawn to UIP for both personal and professional reasons. His wife is also a UI employee, and the executive director role aligned with his experience leading organizations that serve the pharmaceutical and biotechnology industries. He previously founded Genezen, a contract development and manufacturing organization (CDMO) focused on viral vectors used in gene and cell therapies. He also served as CEO of Rimedion, a gene therapy startup developing treatments for rare hematologic disorders.

“UIP was a business I really understood because both organizations face similar challenges in serving the biotech and pharma industry,” Vincent said. “Also, UIP is unique in being the oldest and largest university-affiliated, FDA-registered facility. It seemed that there were a lot of opportunities for UIP, and I love a good challenge.”

That background in cell and gene therapy, along with his broader experience in pharmaceutical development and manufacturing, gives Vincent valuable perspective as he leads UIP. The organization manufactures a wide range of pharmaceutical products, including tablets, capsules, gels, creams, powders, and liquid and lyophilized products in vials. Its capabilities span development from the preclinical stage through commercial supply.

Bindu Gottam, University of Iowa Pharmaceuticals director of Preformulation and Formulation Development, stands at a black laboratory counter with a pen and notebook explaining to two students lyophilization process fundamentals and key considerations for successful product development. The two students wear white lab coats and are listening. Laboratory shelves and bright overhead lights fill the background.
PhD students listen during the 2026 UIP summer Industry Experience program.
Core Growth, Future GMP Training

Vincent takes the helm at a pivotal time for the biotechnology industry. After a downturn that began in 2022, renewed investment is creating fresh opportunities for biotech companies and their manufacturing partners. At the same time, UIP has felt the effects of reduced grant funding for small startups and academic researchers, limiting resources that often support early-stage clinical trial work.

“Building back our core business will be my main focus for the first few years,” Vincent said. “It is often joked that UIP is the university’s best-kept secret. I am hoping to end that by creating more exposure in the industry for UIP.”

Although UIP operates as a CDMO, its connection to the UI College of Pharmacy and the university offers opportunities beyond pharmaceutical manufacturing. Vincent hopes to build on that connection by expanding educational and workforce development opportunities for students and industry professionals.

“I feel that supporting the school’s educational mission is an area where we can offer something unique from other colleges,” Vincent said. “There is a big need in the biotech and pharmaceuticals industry to find employees with experience in Good Manufacturing Practices (GMP). I am hoping to use the expertise we have in house to develop several courses and programs to serve our students and better prepare them to go into the workforce.”

He also aims to offer training for professionals already working in the industry, helping meet workforce needs while raising awareness of UIP, the College of Pharmacy, and the UI.

Since joining UIP, Vincent has been impressed by the knowledge and dedication of its employees. He sees those strengths as an important foundation for the organization’s next chapter.

“Iowa is simply not known as a big biotech state, so it was just really nice to find that we had the skills and experience right here in Iowa City,” Vincent said.